Micromedic – a Cancer Diagnostics Cluster     News
  Micromedic Technologies Ltd. specializes in the development and commercialization of novel and innovative cancer diagnostic products. Our portfolio spans a wide range of cancer and cancer-related indications including colorectal cancer, breast cancer, cervical cancer, bladder cancer, lung cancer, and diagnostic tools for personalized treatment.

Micromedic is a public company traded on the Tel Aviv Stock Exchange (TASE: MCTC).

Micromedic reports success in clinical pilot of its Cervical Cancer diagnostic product in a centeral hospital in Beijing

Zetiq has signed a memorandum of understanding for collaboration in India

Successful interim results in a trial of a test for recurrence of bladder cancer cells in urine specimens

Zetiq received patent approval in Japan for its cell staining technology

Marketing approval for Zetiq's CellDetect in China

BioLight will invest 4 million NIS for additional 5% of Micromedic

Micromedic signed an investment agreement with BioMarCare Technologies Inc.

BioLight acquires 21% of Micromedic

© Micromedic Technologies Ltd. site mapcontact  
Site by Site2goal | Design Studio Michal Lehavi